Form 4: Anika Therapeutics Director Glenn Larsen Granted 14,164 Restricted Stock Units

Anika Therapeutics, Inc. Director Glenn R. Larsen has been granted 14,164 restricted stock units (RSUs) which will vest in 2026, increasing his beneficial ownership to 50,258 shares.

Summary

• Glenn R. Larsen, a Director of Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 20, 2025.
• Each RSU represents a contingent right to receive one share of the Company's common stock.
• The RSUs were acquired at a price of $0, indicating they are part of a compensation package.
• Following this transaction, Mr. Larsen's total beneficial ownership in Anika Therapeutics, Inc. stands at 50,258 shares.
• The RSUs are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates an increase in insider ownership through a standard compensation mechanism, aligning the director's interests with shareholders. This is a routine transaction and does not suggest any negative underlying issues.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• An increase in beneficial ownership by a director can signal confidence in the company's future prospects.

Future Outlook

The acquired Restricted Stock Units are set to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026, indicating a future milestone for the conversion of these contingent rights into common stock.

Industry Context

The grant of Restricted Stock Units (RSUs) to directors is a common practice in the biotechnology and medical device industries, serving as a key component of executive and director compensation packages designed to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice across various industries, including healthcare and biotechnology, similar to companies like Stryker Corporation or Zimmer Biomet Holdings, Inc., which also utilize equity grants to incentivize their leadership.
• The vesting schedule, tied to a future annual meeting or a specific date, is typical for such grants, aiming to retain talent and encourage sustained performance over a defined period.

Related Party Transactions

• The acquisition of 14,164 Restricted Stock Units by Glenn R. Larsen, a Director of Anika Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, as the compensation's ultimate value depends on the company's stock performance.
• Employees: While not directly impacting general employees, such compensation structures for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The Restricted Stock Units will vest on the earlier of the 2026 annual meeting of Anika Therapeutics' stockholders or June 20, 2026, at which point they will convert into shares of common stock.

Key Dates

Keywords

Anika Therapeutics, ANIK, Restricted Stock Units, RSU, Insider Ownership, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant